Premium
Fluoroquinolone levels in healthy dog urine following a 20‐mg/kg oral dose of enrofloxacin exceed mutant prevention concentration targets against E scherichia coli isolated from canine urinary tract infections
Author(s) -
Daniels J. B.,
Tracy G.,
Irom S. J.,
Lakritz J.
Publication year - 2014
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12069
Subject(s) - enrofloxacin , urine , pharmacology , mutant , chemistry , urinary system , medicine , antibiotics , ciprofloxacin , biochemistry , gene
A 3‐day course of oral enrofloxacin is effective for treating uncomplicated urinary tract infection ( UTI ) in dogs when administered 20 mg/kg Q 24 H . However, emergence of fluoroquinolone‐resistant mutants of uropathogens is a concern. Urine concentrations of enrofloxacin and ciprofloxacin were measured in six healthy dogs following dose of enrofloxacin 20 mg/kg. Mutant prevention concentrations of E scherichia coli isolated from canine UTI were also determined against ciprofloxacin. Urine AUC (24)/ MPC ratios considering ciprofloxacin concentrations ranged 3819–7767, indicating that selection of resistant E . coli mutants in dogs with uncomplicated UTI s is unlikely in the bladder given that an AUC (24)/ MPC = 39 is considered to be protective against mutant selection for ciprofloxacin. However, additional studies are required to evaluate the effects of this enrofloxacin treatment protocol on bacteria that colonize anatomic sites where fluoroquinolones achieve lower concentrations compared to the urinary bladder.